
ACT Brief: APAC Trial Advantages, Learning From Setbacks, and Sunharbo Stroke Prevention Approval
11.11.2026
0:00
1:41
In today’s ACT Brief, we examine why APAC is attractive for global Phase III programs, how clinical research professionals can turn a failed pivotal trial into a redesigned success, and how FDA approved Sunharbo to reduce recurrent stroke risk.
Flere episoder fra "Applied Clinical Trials"



Gå ikke glip af nogen episoder af “Applied Clinical Trials” - abonnér på podcasten med gratisapp GetPodcast.








